Expanded access vs clinical trials for pediatric patients

These figures describe regulatory authorization, not treatment efficacy, clinical benefit, or manufacturer willingness to supply the investigational product.

That distinction defines the comparison between expanded access and clinical trials for pediatric patients. A clinical trial is an evidence-generation system. Expanded access is a treatment pathway for an individual child or a small patient group when trial participation is not possible and no satisfactory approved alternative exists. The same investigational therapy may be involved. The regulatory purpose is different.

For pediatric immunology, gene therapy, biologics, and rare immune disorders, this difference affects every operational step: eligibility, consent, monitoring, data collection, manufacturing access, institutional review, and the interpretation of outcomes.

The fundamental divergence: scientific data versus therapeutic intent

Clinical trials and expanded access are not interchangeable routes to the same endpoint.

A clinical trial operates under a predefined protocol. It specifies:

• The target disease and inclusion criteria.
• The dose, schedule, route of administration, and treatment duration.
• Safety monitoring and stopping rules.
• Primary and secondary endpoints.
• Required laboratory, imaging, functional, and immunological assessments.
• Statistical methods for interpreting outcomes.
• Procedures for adverse-event reporting and protocol deviations.

The central output is structured evidence. The trial must characterize safety and estimate efficacy across a defined population. Depending on the phase, it may also evaluate pharmacokinetics, pharmacodynamics, dose escalation, biomarker response, durability, or comparative benefit.

Expanded access has a different primary objective. It permits treatment of a patient with a serious or life-threatening condition when:

1. No satisfactory approved therapy exists.

2. The patient cannot participate in an appropriate clinical trial.

3. Access will not interfere with the conduct or potential success of ongoing clinical investigations.

The treatment remains investigational. The pathway does not convert the product into an approved therapy. It also does not create the same level of evidence as enrollment in a controlled clinical study.

In a pediatric immune deficiency, the trial may require a molecular diagnosis, a defined pathogenic variant, a minimum age, preserved organ function, or a specific disease severity score. An expanded access request may use similar clinical and genetic documentation, but the logic is individualized. The physician must explain why this child cannot enter an available study and why the expected risk is justified by the absence of alternatives.

Clinical trial enrollment is structured around evidence production. Expanded access is structured around an individual treatment decision under regulatory controls.

This difference changes the role of every diagnostic assay. In a trial, sequencing and immunophenotyping may be eligibility tests and stratification biomarkers. Under expanded access, the same assays may be used to establish disease identity, verify the pathogenic variant, document baseline severity, and define a monitoring plan. The assay is not merely a gatekeeper. It becomes part of the justification for treatment and the subsequent assessment of response.

Pediatric clinical trial enrollment: protocol-defined access

A pediatric clinical trial is not simply a list of available drugs. It is a protocol with a fixed operational architecture. A child may be medically appropriate for an investigational therapy but still fail enrollment because the disease definition, age range, prior-treatment history, laboratory thresholds, or geographic requirements do not match the protocol.

The most common enrollment variables include:

• Molecular eligibility. The trial may require a confirmed pathogenic or likely pathogenic variant in a specified gene. A variant of uncertain significance generally does not establish eligibility.
• Phenotypic eligibility. The child may need a documented pattern of infections, inflammatory disease, lymphoproliferation, cytopenias, organ involvement, or immune dysfunction.
• Disease severity. Some protocols require active disease. Others exclude children with rapidly progressive organ damage because the investigational intervention may not provide a sufficiently rapid benefit.
• Previous treatment. Prior immunoglobulin replacement, hematopoietic stem cell transplantation, biologic therapy, corticosteroids, or antimicrobial prophylaxis may affect inclusion.
• Organ function. Hepatic, renal, cardiac, pulmonary, or marrow reserve may be assessed before enrollment.
• Age and body weight. Pediatric protocols often define narrow age bands or dose-adjustment rules.
• Trial capacity. A child can satisfy every scientific criterion and still face a closed cohort, a full site, or a manufacturing delay.

The protocol determines what counts as an acceptable diagnostic result. For example, a trial may accept a validated next-generation sequencing panel if the assay covers the relevant coding regions and has sufficient analytical sensitivity for the variant class under investigation. Another study may require confirmation by an orthogonal method, such as Sanger sequencing, copy-number analysis, RNA testing, or a specialized functional assay.

The distinction between analytical validity and clinical validity is operationally important. Analytical validity addresses whether the assay detects the variant accurately. Clinical validity addresses whether the variant explains the patient’s phenotype. A high-throughput panel may identify a pathogenic variant, but interpretation still depends on inheritance, allele status, population frequency, functional evidence, and phenotype concordance.

A trial’s enrollment team will usually assess the complete diagnostic package rather than one isolated result. In pediatric immunodeficiency, that package can include:

• Complete blood count with differential.
• Lymphocyte subset analysis.
• Quantitative immunoglobulins.
• Vaccine-specific antibody responses.
• T-cell and B-cell functional assays.
• Complement testing.
• Neutrophil oxidative burst or related functional testing.
• Targeted or broad genomic sequencing.
• Copy-number and structural-variant analysis.
• Family testing for segregation.
• Infection history and treatment records.

The resulting pathway is systematic but not necessarily fast. A protocol may reduce ambiguity by defining its criteria in advance. It may also create delays when one missing biomarker, unresolved variant, or repeat sample prevents a final eligibility decision.

Expanded access under 21 CFR 312 Subpart I

Expanded access in the United States is governed by FDA regulations in 21 CFR 312 Subpart I. The regulatory framework covers individual patients, intermediate-size patient populations, and larger treatment protocols. For a single pediatric patient, the treating physician generally serves as the submitting investigator and must provide a clinical rationale for access.

The request must establish several elements:

Serious or life-threatening disease

The condition must carry substantial morbidity, mortality, or irreversible progression. Pediatric primary immunodeficiencies can meet this threshold when recurrent infections, immune dysregulation, malignancy risk, organ damage, or severe inflammation create a significant threat to health.

The label alone is not sufficient. The submission must describe the child’s current clinical status. Relevant evidence may include infection frequency, hospitalization history, antimicrobial resistance, organ involvement, immunological decline, or failure of standard treatment.

No satisfactory approved alternative

Expanded access is not designed to bypass an effective approved therapy because an investigational product appears more attractive. The physician must explain why available treatment is ineffective, contraindicated, inaccessible in the relevant clinical context, or inadequate for the child’s condition.

This assessment can be complex in immunology. Immunoglobulin replacement may control infection risk but not correct an underlying genetic defect. A biologic may suppress inflammation while leaving a major susceptibility to infection. Hematopoietic stem cell transplantation may be potentially curative for a selected disorder but unsuitable because of age, comorbidity, donor constraints, disease status, or transplant-related risk.

The regulatory argument must be specific. A general statement that standard care has failed is weaker than a documented treatment history linked to objective disease activity and relevant biomarkers.

Inability to participate in a clinical trial

Trial participation may be impossible because no suitable study exists, the study excludes the child’s genotype or phenotype, enrollment is closed, the site is inaccessible, or the patient does not meet a critical criterion. The reason must be documented rather than implied.

A child should not be routed to expanded access solely because the family prefers individualized treatment. If an appropriate clinical trial is available and enrollment is feasible, the trial may be the more scientifically and clinically coherent option. Expanded access becomes more relevant when the protocol cannot accommodate the patient or when the patient’s condition makes waiting for enrollment clinically unacceptable.

Risk-benefit justification

The physician must provide a rationale that the potential benefit justifies the foreseeable risks. This assessment is not equivalent to a positive clinical-trial result. Investigational therapies often have incomplete safety data, particularly in children and in rare molecular subgroups.

The submission should connect the expected mechanism to the child’s disease biology. In a gene therapy context, that may require confirmation that the pathogenic variant affects the pathway targeted by the vector or gene-replacement strategy. In a biologic trial, the rationale may depend on a biomarker-defined inflammatory pathway. Mechanistic plausibility does not establish efficacy, but an unlinked mechanism weakens the justification.

Noninterference with clinical investigations

Expanded access must not compromise ongoing clinical trials. This includes interference with recruitment, data integrity, product supply, or the ability to complete a study required for regulatory evaluation.

The product sponsor may therefore evaluate the request against manufacturing capacity, protocol commitments, safety information, and the potential effect on the development program. Regulatory authorization does not remove these constraints.

Required oversight

Expanded access generally requires:

• Authorization from the relevant regulatory authority, such as the FDA or EMA.
• Review and approval by an Institutional Review Board.
• Informed consent from the parent or legally authorized representative, with assent from the child when appropriate.
• Voluntary agreement from the manufacturer to provide the investigational product.
• A physician responsible for treatment, monitoring, and reporting.
• A defined system for adverse-event reporting and clinical follow-up.

The FDA has also provided a two-page form for certain single-patient physician submissions. A short form does not mean a low-evidence submission. The supporting medical record, laboratory data, genomic interpretation, treatment history, and monitoring plan carry the substantive burden.

Expanded access versus clinical trials: operational comparison

The table describes the regulatory architecture, not a universal clinical hierarchy. A clinical trial is not automatically safer for every child, and expanded access is not automatically less rigorous in every individual case. The difference is the level of standardization and the purpose of the data.

For families and clinical teams, the practical question is not simply whether a drug can be accessed. It is whether the available pathway fits the child’s diagnostic certainty, disease trajectory, treatment alternatives, and monitoring capacity.

The reality of approval: high authorization rates, limited clinical conclusions

The approximate 99% approval rate reported for FDA expanded-access applications is frequently misinterpreted. It does not mean that 99% of investigational treatments work. It does not represent a response rate. It does not indicate that the FDA has confirmed the therapy’s benefit for each patient.

The denominator consists of submitted applications. These submissions are typically prepared after clinical and regulatory review has already occurred. Physicians may consult the manufacturer, assess eligibility, review available safety data, and determine whether the request is plausible before submitting it. This selection process can produce a high authorization rate without implying high treatment efficacy.

More than 75% of applications have reportedly been approved within a few days. This can be clinically significant when disease progression is rapid. It does not eliminate the other sources of delay:

• Genomic confirmation may require reanalysis or a second laboratory method.
• The manufacturer may need to review the case before the FDA submission.
• Product manufacturing or release may take longer than regulatory review.
• The IRB may operate on a scheduled meeting cycle unless an emergency process is available.
• Institutional pharmacy, transport, storage, and administration requirements may add time.
• Baseline testing may be extensive, particularly for gene therapy or cellular products.
• Insurance may not cover all treatment-related or administrative costs.

The regulatory clock is therefore only one component of the access timeline.

The evidence generated during expanded access also has a different statistical profile. A single child may show a clinically meaningful response, but the observation lacks the control conditions and sample size required to estimate population-level efficacy. Disease variability, concomitant therapy, regression to the mean, natural history, and measurement bias can all affect interpretation.

That does not make the data useless. Expanded-access outcomes may contribute to safety surveillance, phenotype characterization, biomarker development, and hypothesis generation. They can also document the clinical course of children who would otherwise have no treatment experience with the investigational product. However, these data do not completely substitute for controlled randomized clinical trials in standard FDA or EMA marketing authorization applications.

A rapid authorization decision answers whether access may proceed. It does not answer whether the therapy is effective.

Right to Try versus expanded access

The United States has a parallel pathway under the Right to Try Act, enacted in 2018. The terminology is similar, but the operational requirements differ.

Right to Try is intended for eligible patients with life-threatening conditions who have exhausted approved treatment options and seek access to certain investigational drugs. The investigational product must have completed a Phase 1 clinical trial. The pathway bypasses FDA review, but it does not eliminate the need for a treating physician, informed consent, and manufacturer agreement.

The principal distinctions are:

• FDA involvement. Traditional expanded access requires FDA authorization. Right to Try is designed to proceed without FDA review.
• Development stage. Right to Try requires the investigational drug to have completed Phase 1 testing.
• Eligibility framework. Right to Try applies to a narrower statutory pathway and does not function as a general alternative for every investigational product or every clinical situation.
• Manufacturer participation. The manufacturer remains under no legal obligation to provide the product.
• Institutional oversight. The treating institution and relevant oversight bodies still have responsibilities. Bypassing FDA review does not bypass clinical accountability.
• Evidence limitations. Treatment under Right to Try remains outside the controlled structure of a conventional trial.

For pediatric patients, the presence of a statutory pathway does not guarantee practical access. A child may meet the general clinical description but still lack an available product, a willing manufacturer, sufficient manufacturing capacity, or a physician prepared to assume the treatment and monitoring obligations.

The pathway also does not remove the need for a molecular and clinical diagnosis. If the investigational therapy is designed for a specific genetic defect, the treating team still needs a reliable assay and an interpretation that supports the proposed mechanism. A regulatory route cannot compensate for a weak diagnostic foundation.

The manufacturer is the ultimate gatekeeper

FDA authorization or a Right to Try eligibility assessment does not compel a company to supply an investigational drug. Manufacturer consent is a separate decision.

This is the most important practical constraint in compassionate use for pediatric drugs. The manufacturer may decline because of:

• Insufficient product supply.
• A manufacturing schedule that cannot support an additional patient.
• Concerns about an adverse event or disease-specific risk.
• A need to preserve product for a controlled trial.
• Lack of evidence for the child’s genotype or phenotype.
• Operational limitations at the treatment site.
• Cost-recovery or logistics policies.
• A decision to restrict use while the development program is still being defined.

Companies may also require internal review of the medical record, diagnostic data, previous treatments, and proposed monitoring plan before agreeing to provide the product. The treating physician generally needs to submit a case that is clinically coherent and operationally executable.

Cost is a separate issue. Expanded access can involve the investigational product, preparation, administration, laboratory monitoring, hospitalization, transport, storage, adverse-event management, and long-term follow-up. Coverage policies vary. Insurance or health systems do not universally cover the peripheral administrative and clinical costs associated with expanded access treatment.

A manufacturer’s agreement may therefore be conditional. It may specify the amount of product, the treatment schedule, reporting requirements, follow-up duration, or the circumstances under which further supply will be considered. Access for one treatment cycle does not guarantee continued access.

For gene therapies and cellular products, logistics are particularly restrictive. Product identity, chain of custody, release testing, storage conditions, vector or cell manufacturing, and site qualification can be decisive. In a pediatric setting, body weight and dose scaling can also affect product requirements. These are not administrative details. They determine whether treatment can be delivered safely.

Diagnostic requirements determine the strength of the request

A high-quality expanded-access request is built on a high-confidence diagnosis. The most persuasive documentation links four elements:

1. The child’s phenotype.

2. The molecular or cellular defect.

3. The mechanism of the investigational therapy.

4. The expected clinical endpoint and monitoring strategy.

Targeted sequencing may be appropriate when the phenotype strongly indicates a defined gene or pathway. A broader panel may be preferable when several genes produce overlapping immune phenotypes. Whole-exome sequencing can expand variant discovery across coding regions, while whole-genome sequencing may improve detection of structural variants, noncoding variants, and complex genomic events. None of these methods guarantees diagnostic resolution.

Assay selection should reflect the suspected variant class. Short-read sequencing can be limited for repeat expansions, deep intronic variants, complex rearrangements, and regions with pseudogenes or high homology. Copy-number analysis, RNA studies, long-read sequencing, or functional immunological assays may be required.

The report should distinguish:

• Pathogenic or likely pathogenic variants.
• Variants of uncertain significance.
• Benign or likely benign findings.
• Negative results that reduce but do not eliminate the probability of a genetic disorder.
• Findings requiring orthogonal confirmation.

The phrase negative genetic test is too broad to be analytically useful. A negative result from a narrow panel does not exclude a disorder caused by a gene outside the assay. A negative exome does not exclude regulatory, structural, mosaic, or technically difficult variants. Clinical interpretation must include assay design, coverage, sensitivity, and limitations.

For expanded access, these limitations should be explicit. A physician should not present a molecular hypothesis as an established diagnosis when the result is unresolved. If the treatment is mechanism-specific, uncertainty at the genetic level directly affects the risk-benefit assessment.

Baseline biomarkers and response assessment

The monitoring plan should define measurable outcomes before treatment begins. The endpoint depends on the disease and therapy, but may include:

• Infection frequency and severity.
• Hospitalization or antimicrobial use.
• Immunoglobulin concentrations and replacement requirements.
• Lymphocyte counts and subset recovery.
• T-cell proliferation or cytokine responses.
• Autoantibody levels.
• Inflammatory markers.
• Organ-specific function.
• Viral or microbial burden where relevant.
• Steroid or biologic dose reduction.
• Patient-reported or caregiver-reported functional outcomes.

A biomarker is useful only if its relationship to clinical benefit is understood or at least explicitly qualified. An increase in a lymphocyte subset does not automatically equal immune reconstitution. A reduction in an inflammatory marker does not prove durable disease control. Assay timing, sample handling, laboratory platform, and reference intervals affect interpretation.

Clinical trials usually standardize these measurements across participants. Expanded access may not. The physician therefore bears greater responsibility for selecting assays with adequate specificity, reproducibility, and longitudinal comparability.

Selecting the pathway for a pediatric patient

The route should be chosen through a structured clinical and regulatory assessment. The following sequence is more useful than treating expanded access as a generic escalation after trial failure.

1. Establish the diagnostic substrate

The treating team should define whether the disease is:

• Genetically confirmed.
• Strongly suspected but molecularly unresolved.
• Defined primarily by an immunological phenotype.
• Confirmed by a functional assay.
• Complicated by more than one plausible mechanism.

The level of diagnostic certainty should match the mechanism of the investigational therapy.

2. Map active clinical trials

Trial searches should assess more than the drug name. The relevant variables include disease definition, genotype, age, geographic site, cohort status, prior therapy, organ-function thresholds, and manufacturing availability.

A trial may exist but remain unsuitable because its enrollment criteria do not match the child. Conversely, a trial that appears broad may require a biomarker or functional endpoint unavailable at the referring institution.

3. Define the treatment gap

The clinical team should document why approved treatment is insufficient. This may involve refractory disease, progressive organ damage, unacceptable toxicity, contraindication, or the absence of a therapy that addresses the causal defect.

The treatment gap should be linked to objective findings. Statements without laboratory, clinical, or longitudinal support have limited regulatory value.

4. Evaluate urgency

Urgency is not identical to severity. A child may have severe disease but a stable trajectory, allowing time for trial screening or additional diagnostic work. Another child may have rapidly progressive disease and no feasible study option.

The timeline affects whether traditional expanded access, an emergency request, or another regulatory mechanism is appropriate. It does not remove the need for informed consent or clinical oversight.

5. Confirm operational feasibility

The physician and institution must be able to administer the product and monitor the child. This includes pharmacy capability, laboratory support, adverse-event management, hospitalization capacity, and follow-up.

For gene and cell therapies, site qualification and product logistics may be decisive. A biologic requiring repeated infusion has a different operational profile from a one-time cellular or gene-based intervention.

6. Obtain manufacturer agreement

Manufacturer communication should occur early. Without product supply, regulatory authorization alone has no therapeutic effect.

The company may request a detailed clinical summary, diagnostic reports, prior treatment records, and a proposed monitoring plan. The request should separate established facts from hypotheses and specify the data that will be collected after treatment.

What expanded access can and cannot establish

Expanded access can provide a clinically important option when a child has a serious condition, no satisfactory alternative, and no feasible clinical trial. It can also generate structured observations about tolerability, dosing, immune biomarkers, and individual response.

It cannot establish population-level efficacy from one case. It cannot guarantee durable treatment. It cannot compel the manufacturer to provide the product. It cannot convert an investigational drug into standard care. It cannot remove the possibility of serious toxicity. It cannot guarantee insurance coverage for treatment or monitoring costs.

Clinical trials have their own limitations. They may exclude children with complex comorbidities, rare variants, unstable disease, or previous transplantation. Protocol endpoints may not capture every outcome relevant to the family. Trial enrollment can require travel and repeated assessments. A protocol can also close before a patient completes screening.

The choice is therefore not between a scientifically valid route and an unregulated route. Both pathways require oversight. They differ in purpose, evidence structure, eligibility logic, and control over product supply.

Rigid assessment of clinical utility

For pediatric patients, expanded access is clinically defensible when five conditions align:

• The disease is serious or life-threatening.
• Approved treatment is absent or inadequate.
• A suitable clinical trial is unavailable or infeasible.
• The diagnosis and treatment mechanism are sufficiently supported.
• The treating institution and manufacturer can execute the plan safely.

A clinical trial remains the stronger pathway for systematic evidence generation. It provides standardized eligibility, treatment delivery, endpoint collection, and safety analysis. Expanded access is the more relevant pathway when therapeutic urgency and trial ineligibility converge.

The approximately 99% FDA authorization rate should be read as evidence that well-prepared applications are often approved, not as evidence that investigational therapy is effective. The reported approval speed can reduce regulatory delay, but it does not resolve diagnostic uncertainty, manufacturing constraints, IRB review, or cost coverage.

The practical conclusion is exact: clinical trials optimize data quality across patients; expanded access optimizes individualized treatment access under exceptional conditions. In pediatric immunology, the quality of the diagnostic assay and the precision of the clinical justification determine whether either pathway is scientifically and clinically credible.